Will Casgevy, the first cell therapy using CRISPR gene editing, have net sales >$100M in 2024?
Basic
7
Ṁ320Feb 16
8%
chance
1D
1W
1M
ALL
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Sort by:
Price is $2.2 million per NYTimes: https://web.archive.org/web/20231214145621/https://www.nytimes.com/2023/12/08/health/fda-sickle-cell-crispr.html
So the number of treatments to reach that would actually be quite small. But the article also notes that the capacity will be extremely limited. Vertex has 9 centers approved to offer the treatment, and one of those says they can treat 5-10 a year.
$100 million seems like the right ballpark, and I think the chance they hit that in 2025 seems reasonably high, but for 2024 I'm not optimistic unless the figures from the NYTimes don't tell the full story or I am misreading them.
Related questions
Related questions
Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
77% chance
Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
Will one company of Cult Food Science's portfolio have a yearly revenue of >100M before 2025?
28% chance
Will there be an in-vivo gene therapy that edits multiple genes at once approved anywhere in the world before 2030?
52% chance
Will a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
59% chance
Will I receive any kind of gene therapy created using CRISPR before I die?
59% chance
Will gene editing have cured at least one major disease by 2025?
95% chance
Will biopharma VC funding in one year have exceeded $100 billion USD by 2030?
70% chance
Will precigenetics raise more than 2 million in 2024
88% chance
Will Jazz's Xywav drug sell >$1.4B in the US in 2024?
57% chance